Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Mavefund
Dashboard
NeuBase Therapeutics Inc logo
NBSE

NeuBase Therapeutics Inc

MaveScore 12 Low model confidence
Last Price US$0.38 As of Updating
Market Cap US$20.5m Company size context
7D Performance -6.67% Past 7 days
1Y Performance 98.95% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Sep 30, 2023

992 days old

Market price date

Updating

Refreshing

Coverage

11/16

5 missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 12 Low confidence

Stored data quality

Freshness and coverage checks

Stored company inputs are available, but some dates or model fields are older or incomplete.

11/16 Partial or delayed snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

12/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

0/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

0/15 Weak

Momentum

Momentum needs recent 3-month or 6-month price-change data.

0/15 Needs Data

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin, latest price, 3-month price change, 6-month price change.

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

NeuBase Therapeutics Inc Overview

Industry: Biotechnology

Sector: Healthcare

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NeuBase Therapeutics Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review NeuBase Therapeutics Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



NeuBase Therapeutics Inc Competitors

NeuBase Therapeutics Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

NeuBase Therapeutics Inc

US$0.38

US$20.5m

-6.67%

98.95%